MANHASSET, NY--North Shore University Hospital-Cornell University Medical College has announced the start of a phase I study of continuous infusion interleukin-2 given with a circadian modified pattern (CORN 9476).
MANHASSET, NY--North Shore University Hospital-Cornell UniversityMedical College has announced the start of a phase I study ofcontinuous infusion interleukin-2 given with a circadian modifiedpattern (CORN 9476).
M. Margaret Kemeny, MD, chief, division of surgical oncology,said that the trial is open to all patients with metastatic melanomaor metastatic renal cell carcinoma except those who have alreadyreceived previous IL-2 therapy or have failed two or more chemotherapeuticor immunotherapeutic treatments.
The goals of the study are (1) to identify the optimal cycle ina 24-hour period for the administration of IL-2 as a continuousinfusion and (2) to determine whether increased amounts of IL-2are tolerated with less toxicity using this optimal pattern. Formore information, contact Dr. Kemeny at 516-562-3153.